Vericel Corp
VCEL32.040USD
-1.490-4.44%
Market hours （ET）Quotes delayed by 15 min
1.62BMarket Cap
227.40P/E TTM
More Details of Vericel Corp Company
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adults with deep partial-thickness and/or full-thickness burns.
Company Info
Ticker SymbolVCEL
Company nameVericel Corp
IPO dateFeb 04, 1997
CEOMr. Dominick C. Colangelo
Number of employees357
Security typeOrdinary Share
Fiscal year-endFeb 04
Address64 Sidney St
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02139
Phone17349305555
Websitehttps://vcel.com/
Ticker SymbolVCEL
IPO dateFeb 04, 1997
CEOMr. Dominick C. Colangelo
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
260.28K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
66.21K
--
Mr. Alan L. Rubino
Mr. Alan L. Rubino
Independent Director
Independent Director
45.99K
+7.48%
Dr. Paul K. Wotton, Ph.D.
Dr. Paul K. Wotton, Ph.D.
Independent Director
Independent Director
30.60K
+11.68%
Dr. Robert L. Zerbe, M.D.
Dr. Robert L. Zerbe, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.80K
+12.03%
Mr. Michael Halpin
Mr. Michael Halpin
Chief Operating Officer
Chief Operating Officer
15.63K
+2.77%
Mr. Kevin F. Mclaughlin
Mr. Kevin F. Mclaughlin
Independent Director
Independent Director
15.10K
--
Ms. Lisa Wright
Ms. Lisa Wright
Independent Director
Independent Director
12.65K
+33.86%
Mr. Sean C. Flynn
Mr. Sean C. Flynn
Chief Legal Officer
Chief Legal Officer
971.00
+105.29%
Ms. Heidi M. Hagen
Ms. Heidi M. Hagen
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
260.28K
--
Dr. Jonathan Mark Hopper
Dr. Jonathan Mark Hopper
Chief Medical Officer
Chief Medical Officer
66.21K
--
Mr. Alan L. Rubino
Mr. Alan L. Rubino
Independent Director
Independent Director
45.99K
+7.48%
Dr. Paul K. Wotton, Ph.D.
Dr. Paul K. Wotton, Ph.D.
Independent Director
Independent Director
30.60K
+11.68%
Dr. Robert L. Zerbe, M.D.
Dr. Robert L. Zerbe, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
29.80K
+12.03%
Mr. Michael Halpin
Mr. Michael Halpin
Chief Operating Officer
Chief Operating Officer
15.63K
+2.77%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
MACI
46.30M
88.02%
Epicel
4.96M
9.44%
NexoBrid
1.34M
2.54%
By RegionUSD
Name
Revenue
Proportion
United States
52.60M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
MACI
46.30M
88.02%
Epicel
4.96M
9.44%
NexoBrid
1.34M
2.54%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.89%
The Vanguard Group, Inc.
7.04%
Brown Capital Management, LLC
5.57%
Conestoga Capital Advisors, LLC
4.88%
State Street Global Advisors (US)
4.83%
Other
63.79%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.89%
The Vanguard Group, Inc.
7.04%
Brown Capital Management, LLC
5.57%
Conestoga Capital Advisors, LLC
4.88%
State Street Global Advisors (US)
4.83%
Other
63.79%
Shareholder Types
Shareholders
Proportion
Investment Advisor
64.43%
Investment Advisor/Hedge Fund
38.80%
Pension Fund
2.82%
Research Firm
2.51%
Hedge Fund
1.37%
Bank and Trust
1.08%
Individual Investor
1.06%
Insurance Company
0.10%
Sovereign Wealth Fund
0.06%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
541
57.26M
113.48%
+428.24K
2025Q1
559
55.34M
109.94%
-1.25M
2024Q4
543
54.07M
108.22%
-1.11M
2024Q3
519
52.64M
107.39%
-2.94M
2024Q2
509
52.53M
108.12%
-3.27M
2024Q1
499
52.78M
109.13%
-3.92M
2023Q4
473
53.52M
112.14%
-4.39M
2023Q3
463
53.25M
111.77%
-4.17M
2023Q2
465
51.63M
108.55%
-6.73M
2023Q1
480
52.04M
109.66%
-6.96M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.26M
14.43%
-231.46K
-3.09%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
6.92%
+6.84K
+0.20%
Mar 31, 2025
Brown Capital Management, LLC
2.88M
5.72%
-353.58K
-10.93%
Mar 31, 2025
Conestoga Capital Advisors, LLC
2.06M
4.1%
-7.83K
-0.38%
Mar 31, 2025
State Street Global Advisors (US)
2.44M
4.84%
+32.41K
+1.35%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.19M
4.35%
+146.00K
+7.15%
Mar 31, 2025
Geneva Capital Management LLC
1.37M
2.71%
+265.96K
+24.18%
Mar 31, 2025
Invesco Advisers, Inc.
1.98M
3.94%
+60.96K
+3.17%
Mar 31, 2025
Congress Asset Management Company, LLP
1.48M
2.93%
+22.58K
+1.55%
Mar 31, 2025
GW&K Investment Management, LLC
1.43M
2.85%
+158.47K
+12.44%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Sep 6
Updated: Sat, Sep 6
Name
Proportion
SPDR Portfolio Small Cap ETF (SPSM)
0%
iShares S&P Small-Cap 600 Growth ETF
0%
Schwab U.S. Small-Cap ETF
0%
SPDR S&P 600 Small Cap Growth ETF
0%
iShares Russell 2000 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Biotechnology ETF
0%
iShares Core S&P Small-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
SPDR S&P Biotech ETF
0%
View more
SPDR Portfolio Small Cap ETF (SPSM)
Proportion0%
iShares S&P Small-Cap 600 Growth ETF
Proportion0%
Schwab U.S. Small-Cap ETF
Proportion0%
SPDR S&P 600 Small Cap Growth ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
iShares Biotechnology ETF
Proportion0%
iShares Core S&P Small-Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
SPDR S&P Biotech ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
